Michael Zdanowski - 10 Sep 2022 Form 4 Insider Report for Talaris Therapeutics, Inc. (TALS)

Role: Chief Technology Officer
Signature: /s/ Mary Kay Fenton, attorney-in-fact
Issuer symbol: TALS
Transactions as of: 10 Sep 2022
Transactions value $: $0
Form type: 4
Filing time: 13 Sep 2022, 16:31:17 UTC
Previous filing: 02 Feb 2022
Next filing: 03 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TALS	Common Stock	Award	$0	+120K	+8163.27%	$0.00	121K	10 Sep 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest as to 50% of the underlying shares on July 1, 2023 and the remaining 50% on July 1, 2024, subject to the Reporting Person's continued service on each such vesting date.

Content

The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest as to 50% of the underlying shares on July 1, 2023 and the remaining 50% on July 1, 2024, subject to the Reporting Person's continued service on each such vesting date.